Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（集 團）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to the Approval of Drug Clinical Trial by a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

22 February 2022

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin and Ms. Guan Xiaohui; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

• for identification purposes only

Stock code: 600196	Stock abbreviation: Fosun Pharma	Announcement No.: Lin 2022-026
Bond code: 143020	Bond abbreviation:17 Fosun 01
Bond code: 143422	Bond abbreviation:18 Fosun 01
Bond code: 155067	Bond abbreviation:18 Fosun 02
Bond code: 175708	Bond abbreviation:21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval of Drug

Clinical Trial by a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Fosun Orinove Pharma Tech Inc.* (復星弘創(蘇州)醫藥科技有限公司), "Fosun Orinove"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. * (the "Company"), has received approval from the National Medical Products Administration of the People's Republic of China to initiate clinical trials of ORIN1001 tablets (the "New Drug"), which is researched and developed by Fosun Orinove, for the treatment of idiopathic pulmonary fibrosis (IPF). Fosun Orinove intends to conduct the Phase I clinical trial of the New Drug in China (excluding Hong Kong, Macau and Taiwan, the same below) in due course.

II. Research Progress of the New Drug

The New Drug is a first-in-class small molecule drug with new enzymatic targets, new mechanism of action and new chemical structure type developed by the Group (i.e. the Company and its subsidiaries) on its own for the treatment of advanced solid tumours

1

and idiopathic pulmonary fibrosis. As of the date of this announcement, the New Drug is in Phase I clinical trials in the United States for the treatment of advanced solid tumours and idiopathic pulmonary fibrosis, respectively, and has been approved by the FDA Fast Track Development Program for the treatment of recurrent, refractory and metastatic breast cancer (including triple-negative breast cancer); the New Drug is in Phase I clinical trials in China for the treatment of advanced solid tumours.

As at the date of this announcement, no drugs with the same target have been launched globally.

As of January 2022, the Group has invested approximately RMB 185.42 million (unaudited) in the research and development of the New Drug at this stage.

III. Risk Warning

According to the relevant Chinese regulations, the New Drug has to undergo a series of clinical studies in China and be approved by the national drug review authority before it can be marketed. Based on previous experience, there are certain risks in the R&D of new drugs - for example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and marketing of new drugs is a long-term task involving various uncertainties. Investors are advised to take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 22 February 2022

2